The Ott Group recently announced it has created a subsidiary, Ethos Biosciences, to focus on the design, development, and manufacture of high-quality, easy-to-use diagnostic kits and reagents.
The subsidiary will be based in Philadelphia, taking over the laboratory and office space that formerly housed Glycadia Pharmaceuticals’ diagnostic unit.
Ethos allows Ott Group to design and develop diagnostics and specialty reagents needed to meet the group’s growing customer demands, Michael H. Ott, Ott Group president and CEO, said. The products will be distributed through the group’s sister companies, he said.
“Ethos will continue to provide the excellent products that our customers expect while building our product offerings,” Ryan Ott, Ethos Biosciences president, said. “We also look forward to providing custom development of reagents and diagnostic test kits to help our customers meet their research and clinical goals. The expertise of our scientific staff at Ethos is incredible with more than 100 scientific publications and dozens of patent applications. We intend to build upon the legacy of the Exocell brand.”
The new company acquired Glycadia Pharmaceuticals’ Exocell product line. The line is primarily used in clinical and experimental research of diabetes and diabetes-related vascular and kidney diseases.
Exocell offers products that target hemoglobin, collagen as well as other biological components.